Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.81+0.34 (+1.39%)
Close on Nov 11, 2026Market cap $807.71MP/E 24.8Yield –
Collegium Pharmaceutical ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Collegium Pharmaceutical's ebitda for the twelve months ending Sep 30, 2020 was $39.65M. For fiscal 2019 it was -$23.02M. The highest annual figure on record is -$17.48M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -$23.02M | – |
| FY2018 | Dec 31, 2018 | -$19.61M | – |
| FY2017 | Dec 31, 2017 | -$74.85M | – |
| FY2016 | Dec 31, 2016 | -$93.43M | – |
| FY2015 | Dec 31, 2015 | -$26.74M | – |
| FY2014 | Dec 31, 2014 | -$17.48M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | $19.82M | – |
| Q2 FY2020 | Jun 30, 2020 | $16.75M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.26M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.18M | -119.2% |
| Q3 FY2019 | Sep 30, 2019 | -$6.20M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.81M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.34M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.03M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.20M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.73M | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.45M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.30M | – |
| Q2 FY2017 | Jun 30, 2017 | -$21.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$27.28M | – |
See a number that looks wrong?